Lin Wang

发表

Phase I and pharmacokinetic study of dasatinib and cetuximab in patients with advanced solid malignancies

A. Egloff, J. Grandis, A. Argiris, 2012, Investigational New Drugs.

First-in-human phase I study of BPI-9016M, a dual MET/Axl inhibitor, in patients with non-small cell lung cancer

Yuankai Shi, X. Hao, P. Hu, 2020, Journal of Hematology & Oncology.

Role of chemokine-mediated angiogenesis in resistance towards crizotinib and its reversal by anlotinib in EML4-ALK positive NSCLC

N. Lou, X. Hao, Yu-tao Liu, 2022, Journal of translational medicine.

[Efficacy of Cetuximab in Combination with Chemotherapy in Advanced Non-small Cell Lung Cancer].

Junling Li, Yuankai Shi, Yan Wang, 2016, Zhongguo fei ai za zhi = Chinese journal of lung cancer.

Addition of rituximab is not associated with survival benefit compared with CHOP alone for patients with stage I diffuse large B-cell lymphoma.

P. Liu, Yuankai Shi, Weihu Wang, 2015, Chinese journal of cancer research = Chung-kuo yen cheng yen chiu.

Open-label, Multicenter, Phase II Study of RC48-ADC, a HER2-Targeting Antibody–Drug Conjugate, in Patients with Locally Advanced or Metastatic Urothelial Carcinoma

Jiyan Liu, J. Ying, X. Yao, 2020, Clinical Cancer Research.

Sorafenib in metastatic radioactive iodine-refractory differentiated thyroid cancer: A pilot study.

Yang Luo, P. Xing, Yuankai Shi, 2014, Molecular and clinical oncology.

Perioperative treatment and biomarker analysis of LP002, an anti‐PD‐L1 antibody, plus chemotherapy in resectable gastric and gastroesophageal junction cancer

Yong Li, Bo Zhang, Jian-ping Xu, 2022, Cancer medicine.

Efficacy of dacomitinib in patients with EGFR‐mutated NSCLC and brain metastases

P. Xing, Junling Li, Yan Wang, 2021, Thoracic cancer.

A phase I study of different doses and frequencies of pegylated recombinant human granulocyte-colony stimulating factor (PEG rhG-CSF) in patients with standard-dose chemotherapy-induced neutropenia.

Yuankai Shi, Xiaohong Han, Yuan-yuan Song, 2017, Chinese journal of cancer research = Chung-kuo yen cheng yen chiu.

Comparison of gemcitabin, cisplatin, and dexamethasone (GDP), CHOP, and CHOPE in the first-line treatment of peripheral T-cell lymphomas

P. Liu, P. Xing, Yuankai Shi, 2016, Hematology.

Suitability of Surgical Tumor Tissues, Biopsy, or Cytology Samples for Epidermal Growth Factor Receptor Mutation Testing in Non–Small Cell Lung Carcinoma Based on Chinese Population

Yuankai Shi, Sheng Yang, Yan Sun, 2014, Translational oncology.

Comprehensive analysis of treatment modes and clinical outcomes of small cell lung cancer transformed from epidermal growth factor receptor mutant lung adenocarcinoma

P. Xing, Junling Li, Yan Wang, 2021, Thoracic cancer.

First-line treatment with chemotherapy plus cetuximab in Chinese patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck: Efficacy and safety results of the randomised, phase III CHANGE-2 trial.

Liangfang Shen, Xiao-dong Zhu, Jifeng Feng, 2021, European journal of cancer.

Icotinib as initial treatment in lung adenocarcinoma patients with brain metastases

Yuankai Shi, Jian-ping Xu, Xiaoyan Liu, 2016, Thoracic cancer.

Efficacy and safety of geptanolimab (GB226) for relapsed or refractory peripheral T cell lymphoma: an open-label phase 2 study (Gxplore-002)

Z. Ge, Yuankai Shi, Liping Xie, 2021, Journal of Hematology & Oncology.

miR-130a regulates macrophage polarization and is associated with non-small cell lung cancer.

Yuankai Shi, X. Hao, Bin Wang, 2015, Oncology reports.

Co‐mutational assessment of circulating tumour DNA (ctDNA) during osimertinib treatment for T790M mutant lung cancer

X. Yi, P. Liu, Y. Guan, 2019, Journal of cellular and molecular medicine.

Analysis of clinicopathological features of the echinoderm microtubule‐associated protein‐like‐4‐anaplastic lymphoma kinase fusion gene in Chinese patients with advanced non‐small‐cell lung cancer

Yuankai Shi, Jun-ling Li, X. Hao, 2014, Thoracic cancer.

Potential predictive value of serum targeted metabolites and concurrently mutated genes for EGFR-TKI therapeutic efficacy in lung adenocarcinoma patients with EGFR sensitizing mutations.

Yuankai Shi, Xiaohong Han, Lin Wang, 2020, American journal of cancer research.

Safety, tolerability, and pharmacokinetics of simotinib, a novel specific EGFR tyrosine kinase inhibitor, in patients with advanced non-small cell lung cancer: results of a phase Ib trial

Yuankai Shi, Ning Li, Sheng Yang, 2019, Cancer management and research.

Clinical Characteristics and Treatment Outcomes of 65 Patients With BRAF-Mutated Non-small Cell Lung Cancer

P. Xing, Junling Li, Yan Wang, 2020, Frontiers in Oncology.

A prognostic model for platinum‐doublet as second‐line chemotherapy in advanced non‐small‐cell lung cancer patients

P. Xing, Jun-ling Li, Yan Wang, 2016, Cancer medicine.

Clinical features, survival and prognostic factors of primary testicular diffuse large B-cell lymphoma.

P. Liu, Yuankai Shi, Jian-liang Yang, 2014, Chinese journal of cancer research = Chung-kuo yen cheng yen chiu.

The prognostic significance of the circumferential resection margin in esophageal squamous cell carcinoma patients without neoadjuvant treatment

L. Xue, Zhao-yang Yang, J. Qin, 2022, BMC Cancer.

Efficacy and Safety of the Biosimilar IBI301 Plus Standard CHOP (I-CHOP) in Comparison With Rituximab Plus CHOP (R-CHOP) in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL): A Randomized, Double-Blind, Parallel-Group, Phase 3 Trial

W. Xu, Z. Cai, Jing Liu, 2021, Advances in Therapy.

Prognostic and predictive impact of neutrophil‐to‐lymphocyte ratio and HLA‐I genotyping in advanced esophageal squamous cell carcinoma patients receiving immune checkpoint inhibitor monotherapy

Y. Jiao, Jiachen Xu, H. Mo, 2022, Thoracic cancer.

miR-130 a regulates macrophage polarization and is associated with non-small cell lung cancer

Yuankai Shi, X. Hao, Bin Wang, 2022 .

Suitability of Surgical Tumor

Yuankai Shi, Sheng Yang, Yan Sun, 2014 .

Efficacy and safety of osimertinib plus anlotinib in advanced non‐small‐cell lung cancer patients after drug resistance

Jun Zhao, Xingsheng Hu, Lin Wang, 2023, Thoracic cancer.

Safety and activity of WX-0593 (Iruplinalkib) in patients with ALK- or ROS1-rearranged advanced non-small cell lung cancer: a phase 1 dose-escalation and dose-expansion trial

He-long Zhang, Yunpeng Liu, Yanqiu Zhao, 2022, Signal Transduction and Targeted Therapy.

First-line icotinib versus cisplatine/pemetrexed plus pemetrexed maintenance therapy in lung adenocarcinoma patients with sensitizing EGFR mutation (CONVINCE).

B. Han, He-long Zhang, Yunpeng Liu, 2016 .

P2.03a-024 The Clinical Efficacy and Safety of Paclitaxel Liposome on the Patients with Non-Small Cell Lung Cancer: A Meta-Analysis: Topic: Clinical Trials

P. Xing, Lin Lin, Xingsheng Hu, 2017 .

Efficacy and Safety of Disitamab Vedotin in Patients With Human Epidermal Growth Factor Receptor 2–Positive Locally Advanced or Metastatic Urothelial Carcinoma: A Combined Analysis of Two Phase II Clinical Trials

Yanxia Shi, Y. Ling, Lin Wang, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.